Twice-per-weekSelinexor, 2 Days Melphalan

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-09-30

Summary

Twice-per-week Selinexor, 2 days Melphalan plus BU2FLU3 compared with BU3FLU5 for elder high-risk acute myeloid leukemia undergoing allogenic hematopoietic cell transplantation: a multi-center randomized phase 3 trial

• Phase: PHASE3

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Treatments: fludarabine; Melphalan; selinexor